XFOR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.62%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $491,874.90

X4 Pharmaceuticals Insider Trading History Chart

X4 Pharmaceuticals Share Price & Price History

^$0.34

▼ -0.03 (-8.10%)

As of 11/20/2024 01:00 AM ET

Days: 30 | 90 | 365

When it comes to NVDA… “acceleration cycles” are the key

From DTI | Ad

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

X4 Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/15/2024	Paula Ragan	CEO	Sell	31,897	$0.56	$17,862.32	1,025,816
10/7/2024	Adam S. Mostafa	CFO	Sell	230,645	$0.55	$126,854.75
10/7/2024	Mark Baldry	Insider	Sell	11,127	$0.58	$6,453.66	48,509
10/7/2024	Mary Dibiase	COO	Sell	67,695	$0.57	$38,586.15	452,060
10/7/2024	Paula Ragan	CEO	Sell	239,436	$0.55	$131,689.80	1,057,713
3/11/2024	Adam S. Mostafa	CFO	Sell	52,500	$0.88	$46,200.00
3/11/2024	Arthur Taveras	Insider	Sell	14,235	$0.88	$12,526.80	234,301
3/11/2024	Mary Dibiase	COO	Sell	15,409	$0.88	$13,559.92	291,752
3/11/2024	Paula Ragan	CEO	Sell	49,678	$0.88	$43,716.64	765,068
2/12/2024	Adam S. Mostafa	CFO	Sell	27,721	$1.01	$27,998.21	52,500
2/12/2024	Arthur Taveras	Insider	Sell	787	$1.01	$794.87	248,536
2/12/2024	Mary Dibiase	COO	Sell	3,683	$1.01	$3,719.83	307,161
2/12/2024	Paula Ragan	CEO	Sell	21,695	$1.01	$21,911.95	814,746
11/3/2023	Paula Ragan	CEO	Sell	39,906	$0.90	$35,915.40	836,441
11/1/2023	Adam S. Mostafa	CFO	Sell	230,645	$0.73	$168,370.85	80,221
11/1/2023	Mark Baldry	Insider	Sell	10,257	$0.73	$7,487.61	24,690
11/1/2023	Mary Dibiase	COO	Sell	67,695	$0.73	$49,417.35	310,844
11/1/2023	Paula Ragan	CEO	Sell	199,531	$0.73	$145,657.63	876,347
9/8/2023	Mary Dibiase	COO	Sell	2,642	$1.25	$3,302.50	147,894
8/18/2023	Michael S Wyzga	Director	Buy	25,000	$1.20	$30,000.00	76,667
8/10/2023	Murray Stewart	Insider	Sell	130,056	$1.06	$137,859.36	146,504
6/30/2023	Adam S. Mostafa	CFO	Sell	2,641	$1.89	$4,991.49	80,221
6/30/2023	Mary Dibiase	COO	Sell	464	$1.89	$876.96	150,536
6/23/2023	Adam S. Mostafa	CFO	Sell	5,417	$1.93	$10,454.81	82,862
6/23/2023	Mary Dibiase	COO	Sell	857	$1.93	$1,654.01	151,000
6/23/2023	Paula Ragan	CEO	Sell	6,724	$1.92	$12,910.08	543,797
6/15/2023	Adam S. Mostafa	CFO	Sell	5,417	$2.22	$12,025.74	88,279
6/15/2023	Mary Dibiase	COO	Sell	857	$2.23	$1,911.11	151,857
6/15/2023	Paula Ragan	CEO	Sell	6,724	$2.23	$14,994.52	550,521
5/31/2023	Paula Ragan	CEO	Sell	6,292	$1.95	$12,269.40	557,245
5/17/2023	Israel Niv	Director	Sell	422	$3.32	$1,401.04	67,218
5/17/2023	Tuvia Barlev	CEO	Sell	2,107	$3.32	$6,995.24	163,598
2/13/2023	Adam S. Mostafa	CFO	Sell	27,721	$0.93	$25,780.53	146,196
2/13/2023	Arthur Taveras	Insider	Sell	928	$0.93	$863.04	103,179
2/13/2023	Mary Dibiase	COO	Sell	4,348	$0.93	$4,043.64	170,906
2/13/2023	Paula Ragan	CEO	Sell	21,695	$0.93	$20,176.35	613,215
6/3/2022	Paula Ragan	CEO	Sell	6,292	$1.21	$7,613.32	661,806

Download Our Tesla Ebook For Free

From DTI | Ad

Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

SEC Filings (Institutional Ownership Changes) for X4 Pharmaceuticals (NASDAQ:XFOR)

72.03% of X4 Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

X4 Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/19/2024	Barclays PLC	277,682	$0.19M	0.0%	+196.0%	0.163%
11/16/2024	Geode Capital Management LLC	3,447,512	$2.31M	0.0%	-1.9%	2.046%
11/15/2024	Barclays PLC	277,682	$0.19M	0.0%	+196.0%	0.165%
11/15/2024	K2 Principal Fund L.P.	89,158	$60K	0.0%	-81.8%	0.053%
11/15/2024	XTX Topco Ltd	157,642	$0.11M	0.0%	+41.7%	0.094%
11/15/2024	Jane Street Group LLC	248,447	$0.17M	0.0%	+103.4%	0.147%
11/15/2024	State Street Corp	2,952,895	$1.98M	0.0%	+6.8%	1.752%
11/15/2024	Stifel Financial Corp	122,448	$82K	0.0%	-25.5%	0.073%
11/15/2024	Point72 Asset Management L.P.	625,052	$0.42M	0.0%	+15.1%	0.371%
11/14/2024	Verition Fund Management LLC	44,355	$30K	0.0%	N/A	0.026%
11/14/2024	Sio Capital Management LLC	1,303,508	$0.87M	0.3%	-47.9%	0.774%
11/5/2024	GSA Capital Partners LLP	507,694	$0.34M	0.0%	N/A	0.301%
10/3/2024	SG Americas Securities LLC	55,004	$37K	0.0%	N/A	0.033%
8/19/2024	Point72 Asset Management L.P.	543,084	$0.32M	0.0%	-16.4%	0.323%
8/15/2024	AQR Capital Management LLC	424,042	$0.25M	0.0%	+1,080.3%	0.252%
8/14/2024	K2 Principal Fund L.P.	489,158	$0.28M	0.1%	N/A	0.291%
8/13/2024	Ensign Peak Advisors Inc	2,546,458	$1.48M	0.0%	+4.6%	1.516%
8/12/2024	XTX Topco Ltd	111,245	$65K	0.0%	N/A	0.066%
8/1/2024	Rhumbline Advisers	187,246	$0.11M	0.0%	+14.6%	0.111%
7/26/2024	Bank of New York Mellon Corp	469,372	$0.27M	0.0%	+39.7%	0.279%
5/15/2024	Price T Rowe Associates Inc. MD	39,307	$55K	0.0%	+46.7%	0.023%
5/10/2024	Vanguard Group Inc.	7,827,727	$10.88M	0.0%	-2.3%	4.661%
5/7/2024	SG Americas Securities LLC	20,822	$29K	0.0%	-56.3%	0.012%
5/3/2024	GSA Capital Partners LLP	321,021	$0.45M	0.0%	-66.0%	0.191%
5/1/2024	BNP Paribas Financial Markets	61,575	$86K	0.0%	-78.3%	0.037%
3/18/2024	Kingdon Capital Management L.L.C.	3,473,683	$2.91M	0.4%	+76.0%	2.076%
2/13/2024	Bain Capital Life Sciences Investors LLC	16,915,784	$14.18M	1.4%	+6.0%	10.112%
2/13/2024	Armistice Capital LLC	1,936,000	$1.62M	0.0%	-17.8%	1.157%
1/12/2024	SG Americas Securities LLC	47,668	$40K	0.0%	+38.8%	0.028%
11/22/2023	Polar Capital Holdings Plc	7,500,000	$8.18M	0.1%	-25.0%	4.483%
11/15/2023	GSA Capital Partners LLP	621,587	$0.68M	0.1%	N/A	0.372%
11/15/2023	Armistice Capital LLC	2,356,000	$2.57M	0.0%	-20.8%	1.408%
11/14/2023	Schonfeld Strategic Advisors LLC	586,042	$0.64M	0.0%	-40.4%	0.350%
11/14/2023	Stonepine Capital Management LLC	5,273,685	$5.75M	1.9%	+14.5%	3.152%
11/14/2023	Monashee Investment Management LLC	427,265	$0.47M	0.2%	-25.4%	0.255%
11/7/2023	Barclays PLC	382,134	$0.42M	0.0%	+334.8%	0.232%
10/13/2023	SG Americas Securities LLC	34,340	$37K	0.0%	N/A	0.021%
9/21/2023	Barclays PLC	87,879	$0.17M	0.0%	N/A	0.053%
8/24/2023	Perceptive Advisors LLC	3,545,454	$6.88M	0.2%	-22.0%	2.156%
8/16/2023	Stonepine Capital Management LLC	4,605,263	$8.93M	3.2%	N/A	3.768%
8/15/2023	Bain Capital Life Sciences Investors LLC	15,960,588	$30.96M	3.2%	+30.8%	13.060%
8/14/2023	Polar Capital Holdings Plc	5,000,000	$9.70M	0.1%	N/A	4.091%
8/11/2023	AWM Investment Company Inc.	100,000	$0.19M	0.0%	N/A	0.082%
8/10/2023	Monashee Investment Management LLC	572,784	$1.11M	0.3%	N/A	0.469%
8/10/2023	Private Advisor Group LLC	19,800	$38K	0.0%	N/A	0.016%
8/7/2023	Principal Financial Group Inc.	13,804	$27K	0.0%	N/A	0.011%
8/7/2023	Royce & Associates LP	53,490	$0.10M	0.0%	N/A	0.044%
8/4/2023	American International Group Inc.	59,261	$0.12M	0.0%	N/A	0.048%
7/27/2023	Virtu Financial LLC	15,077	$29K	0.0%	-86.7%	0.012%
7/24/2023	Vontobel Holding Ltd.	45,000	$87K	0.0%	N/A	0.037%
7/19/2023	Grimes & Company Inc.	15,000	$29K	0.0%	N/A	0.012%
5/15/2023	Ghost Tree Capital LLC	850,000	$0.74M	0.2%	-15.0%	0.696%
5/12/2023	Scoggin Management LP	484,796	$0.57M	0.3%	N/A	0.397%
5/12/2023	CIBC Private Wealth Group LLC	41,500	$36K	0.0%	N/A	0.034%
5/10/2023	Landscape Capital Management L.L.C.	42,252	$37K	0.0%	N/A	0.035%
5/10/2023	Simplify Asset Management Inc.	400,000	$0.35M	0.0%	N/A	0.327%
5/1/2023	Virtu Financial LLC	113,489	$99K	0.0%	N/A	0.094%
2/10/2023	NEA Management Company LLC	11,736,793	$11.66M	0.7%	+79.9%	16.952%
2/7/2023	Lynwood Capital Management Inc.	2,155,100	$2.14M	2.6%	N/A	3.113%
11/15/2022	Tri Locum Partners LP	2,504,006	$4.28M	1.2%	+44.0%	3.617%
11/15/2022	Parkman Healthcare Partners LLC	950,000	$1.63M	0.5%	N/A	1.372%
11/15/2022	Bain Capital Life Sciences Investors LLC	6,389,436	$10.93M	1.3%	+111.6%	9.228%
11/14/2022	NEA Management Company LLC	6,523,157	$11.16M	0.6%	N/A	9.422%
11/14/2022	Cormorant Asset Management LP	830,654	$1.42M	0.1%	+698.9%	1.200%
11/14/2022	Point72 Asset Management L.P.	2,546,446	$4.35M	0.0%	+55.9%	3.678%
11/14/2022	Boothbay Fund Management LLC	58,760	$100K	0.0%	-67.3%	0.085%
11/14/2022	AXA S.A.	4,126,460	$7.06M	0.0%	+258.7%	5.960%
11/10/2022	Connor Clark & Lunn Investment Management Ltd.	23,065	$39K	0.0%	N/A	0.033%
10/17/2022	LexAurum Advisors LLC	16,000	$27K	0.0%	N/A	0.023%
8/12/2022	Ikarian Capital LLC	1,679,748	$1.62M	0.3%	+22.4%	5.449%
5/12/2022	AIGH Capital Management LLC	997,719	$1.75M	0.4%	-31.9%	3.237%
4/14/2022	Minot Wealth Management LLC	55,000	$96K	0.0%	N/A	0.179%
2/15/2022	Kennedy Capital Management Inc.	131,501	$0.30M	0.0%	N/A	0.532%
2/14/2022	Point72 Asset Management L.P.	1,633,204	$3.74M	0.0%	N/A	6.610%
2/14/2022	Sio Capital Management LLC	276,909	$0.63M	0.2%	-65.6%	1.121%
2/10/2022	Acadian Asset Management LLC	57,270	$0.13M	0.0%	N/A	0.232%
2/10/2022	AIGH Capital Management LLC	1,464,099	$3.35M	1.0%	-12.0%	5.926%
2/10/2022	Connor Clark & Lunn Investment Management Ltd.	12,786	$29K	0.0%	N/A	0.052%
12/29/2021	Hudson Bay Capital Management LP	45,893	$0.24M	0.0%	-73.4%	0.186%
11/17/2021	Altium Capital Management LP	804,598	$4.26M	0.9%	N/A	3.256%
11/15/2021	Marshall Wace LLP	25,223	$0.13M	0.0%	+84.0%	0.102%
11/15/2021	AXA S.A.	590,269	$3.12M	0.0%	+3.8%	2.389%
11/12/2021	Trexquant Investment LP	16,625	$88K	0.0%	-34.3%	0.067%
11/12/2021	Renaissance Technologies LLC	120,394	$0.64M	0.0%	-7.9%	0.487%
11/12/2021	AIGH Capital Management LLC	1,664,540	$8.81M	1.9%	+15.7%	6.737%
11/9/2021	Barclays PLC	9,899	$52K	0.0%	-39.7%	0.040%
11/9/2021	BlackRock Inc.	268,450	$1.42M	0.0%	+2.0%	1.086%
11/9/2021	Monashee Investment Management LLC	561,421	$2.97M	0.5%	-2.3%	2.272%
8/27/2021	Endurant Capital Management LP	70,969	$0.46M	0.1%	-53.3%	0.286%
8/25/2021	Marshall Wace LLP	13,709	$89K	0.0%	N/A	0.055%
8/18/2021	Ikarian Capital LLC	2,719,290	$17.68M	1.4%	+4.0%	10.942%
8/17/2021	Worth Venture Partners LLC	334,684	$2.18M	0.8%	N/A	1.347%
8/17/2021	Millennium Management LLC	386,007	$2.51M	0.0%	N/A	1.553%
8/17/2021	Boothbay Fund Management LLC	328,209	$2.13M	0.1%	+6.4%	1.321%
8/17/2021	BVF Inc. IL	847,879	$5.51M	0.2%	-22.3%	3.412%
8/16/2021	LMR Partners LLP	10,152	$66K	0.0%	N/A	0.041%
8/16/2021	Cubist Systematic Strategies LLC	13,135	$85K	0.0%	N/A	0.053%
8/16/2021	State Street Corp	48,480	$0.32M	0.0%	-82.5%	0.195%
8/16/2021	Tibra Equities Europe Ltd	48,400	$0.32M	0.1%	N/A	0.195%
8/16/2021	Goldman Sachs Group Inc.	54,007	$0.35M	0.0%	-35.0%	0.217%

Data available starting January 2016

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Today's Range

Now: $0.34

$0.31

$0.36

50 Day Range

MA: $0.57

$0.28

$0.72

52 Week Range

Now: $0.34

$0.26

$1.60

Volume

3,220,296 shs

Average Volume

2,369,976 shs

Market Capitalization

$58.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Who are the company insiders with the largest holdings of X4 Pharmaceuticals?: X4 Pharmaceuticals' top insider shareholders include:
Paula Ragan (CEO)
Mary Dibiase (COO)
Arthur Taveras (Insider)
Tuvia Barlev (CEO)
Murray Stewart (Insider)
Adam S Mostafa (CFO)
Michael S Wyzga (Director)
Israel Niv (Director)
Mark Baldry (Insider)
Adam S Mostafa (CFO)
Learn More about top insider investors at X4 Pharmaceuticals.
Who are the major institutional investors of X4 Pharmaceuticals?: X4 Pharmaceuticals' top institutional investors include:
Geode Capital Management LLC — 2.05%
State Street Corp — 1.75%
Sio Capital Management LLC — 0.77%
Point72 Asset Management L.P. — 0.37%
GSA Capital Partners LLP — 0.30%
Barclays PLC — 0.16%
Learn More about top institutional investors of X4 Pharmaceuticals stock.
Which major investors are selling X4 Pharmaceuticals stock?: During the last quarter, XFOR stock was sold by these institutional investors:
Sio Capital Management LLC
K2 Principal Fund L.P.
Geode Capital Management LLC
Stifel Financial Corp
In the last year, company insiders that have sold X4 Pharmaceuticals company stock include:
Paula Ragan (CEO)
Mary Dibiase (COO)
Arthur Taveras (Insider)
Tuvia Barlev (CEO)
Murray Stewart (Insider)
Adam S Mostafa (CFO)
Learn More investors selling X4 Pharmaceuticals stock.
Which major investors are buying X4 Pharmaceuticals stock?: In the last quarter, XFOR stock was purchased by institutional investors including:
GSA Capital Partners LLP
State Street Corp
Barclays PLC
Barclays PLC
Jane Street Group LLC
Point72 Asset Management L.P.
SG Americas Securities LLC
XTX Topco Ltd